General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-26 | 2024-03 | 2.26 | 2.31 | 0.05 | 2.21% |
2024-02-02 | 2023-12 | 2.76 | 2.79 | 0.03 | 1.09% |
2023-10-27 | 2023-09 | 2.86 | 2.95 | 0.09 | 3.15% |
2023-07-27 | 2023-06 | 2.79 | 2.91 | 0.12 | 4.30% |
2023-04-27 | 2023-03 | 2.44 | 2.46 | 0.02 | 0.82% |
2023-02-09 | 2022-12 | 3.54 | 3.6 | 0.06 | 1.69% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-09-28 | Raymond James | Upgrade | Outperform | |
2023-07-27 | Piper Sandler | Upgrade | Overweight | Overweight |
2023-07-24 | William Blair | Upgrade | Market Perform | |
2023-07-13 | HSBC | Upgrade | Buy | |
2023-07-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-02-28 | BUCKBEE KEVIN K | Officer | 6.98K | Sale |
2024-03-19 | DONOGHOE NICHOLAS | Officer | 55.90K | Sale |
2024-02-27 | GONZALEZ RICHARD A | Chief Executive Officer | 519.10K | Sale |
2024-02-14 | HUDSON THOMAS J | Officer | 127.90K | Stock Award(Grant) |
2024-02-28 | MICHAEL ROBERT A. | President | 98.65K | Sale |
2024-02-22 | REENTS SCOTT T. | Chief Financial Officer | 15.43K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 159.30M | 21.46B | 9.03% |
2023-06-29 | Blackrock Inc. | 139.16M | 18.75B | 7.88% |
2023-06-29 | State Street Corporation | 78.18M | 10.53B | 4.43% |
2023-06-29 | JP Morgan Chase & Company | 56.77M | 7.65B | 3.22% |
2023-06-29 | Capital International Investors | 43.15M | 5.81B | 2.44% |
2023-06-29 | Geode Capital Management, LLC | 34.95M | 4.71B | 1.98% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 55.03M | 7.41B | 3.12% |
2023-06-29 | Vanguard 500 Index Fund | 42.01M | 5.66B | 2.38% |
2023-05-30 | Fidelity 500 Index Fund | 19.79M | 2.73B | 1.12% |
2023-08-30 | SPDR S&P 500 ETF Trust | 19.43M | 2.86B | 1.10% |
2023-09-29 | American Mutual Fund Inc | 17.76M | 2.65B | 1.01% |
2023-08-30 | iShares Core S&P 500 ETF | 16.50M | 2.43B | 0.93% |
Dividend | Date |
---|---|
1.55 | 2024-04-12 |
1.55 | 2024-01-15 |
1.55 | 2024-01-12 |
1.48 | 2023-10-12 |
1.48 | 2023-07-14 |
1.48 | 2023-07-13 |
Will add in 70’s
Upcoming dividend and stock markets back! Oct 14th payday. Back up the brinks greatest dividend ever.
$ABBV Their best drug is botox and nobody is getting that done. Not sure why anyone would be bullish at this time. Humira expiring. Govt lowering drug prices. bad fundamentals. Market still in bearish momentum. Wake up people. Its a bull trap and the bagholders gonna drag you down. Little premature $PFE
$ABBV Come back october 14th. This is a bull trap week. Will be back for ex-dividend date to selloff later. Pop & drop yall bunch. C u on october 14th. Not falling for this bull trap. RBG death means no time for stimulus
$ABBV be greedy when others are doubtful
This puppy is a buy all day!! I see revs as a slam dunk!!
$ABBV AbbVie's upadacitinib successful in second pivotal dermatitis study https://seekingalpha.com/news/3593088
please share Amazing 1st screener app With free news : Android: https://dwz1.cc/zkNVfOg
iOS: https://dwz1.cc/jFICJiK
The Best Stock Screener App Review So Far:
https://dwz1.cc/CjfRfWk
Minutes ago, Yahoo News has Good News on ABBV
https://finance.yahoo.com/amphtml/news/increased-earnings-estimates-seen-abbvie-125712186.html
Its not expensive and its not to late to get in ABBV has a price target of 88 from CFRA .
Earlier today investors were concerned that Allergan was going to charge more for the deal but in extended hours Allergan and ABBV released that their deal was still on for May, as is. See Seeking Alpha. BUY BUY BUY
AbbVie HIV drug being investigated as potential treatment COVID 19
ABBV BEATS!!!
Q4 Non-GAAP EPS of $2.21 BEATS by $0.02; GAAP EPS of $1.88 BEATS by $0.05.
Revenue of $8.7B BEATS by $20M !!!
Shares +1.54% PM.
AbbVie forecasts upbeat 2020 profit.
Reuters:
https://www.cnbc.com/2020/02/07/reuters-america-abbvie-leans-on-new-treatments-to-forecast-upbeat-2020-profit.html?__source=iosappshare|com.apple.UIKit.activity.CopyToPasteboard